首页> 美国卫生研究院文献>World Journal of Gastroenterology >Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma
【2h】

Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma

机译:三维保形放疗联合经导管动脉化疗栓塞治疗肝细胞癌的疗效和预后因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To evaluate the therapeutic efficacy of three-dimensional conformal radiotherapy (3D-CRT) combined with transcatheter arterial chemoembolization (TACE) on the patients with hepatocellular carcinoma (HCC).METHODS: Between 1998 and 2001, 94 patients with HCC received 3D- CRT combined with TACE. A total 63 patients had a Okuda stage I lesion and 31 patients had stage II. The median tumor size was 10.7 cm (range 3.0-18 cm), and liver cirrhosis was present in all the patients. There were 43 cases of class A and 51 class B. TACE was performed using lipiodol, 5-fluorouracil, cisplatin, doxorubicin hydrochloride and mitomycin, followed by gelatin sponge cubes. Fifty- nine patients received TACE only one time, while the others 2 to 3 times. 3D-CRT was started 3-4 wk after TACE. All patients were irradiated with a stereotactic body frame and received 4-8 Gy single high-dose radiation for 8-12 times at the isocenter during a period of 17-26 d (median 22 d).RESULTS: The median follow-up was 37 mo (range 10-48 mo) after diagnosis. The response rate was 90.5%. The overall survival rate at 1-, 2-, and 3- year was 93.6%, 53.8% and 26.0% respectively, with the median survival of 25 mo. On univariate analysis, age (P = 0.026), Child-Pugh classification for cirrhosis of liver ( P = 0.010), Okuda stage (P = 0.026), tumor size (P = 0.000), tumor type (P = 0.029), albuminemia (P = 0.035), and radiation dose (P = 0.000) proved to be significant factors for survival. On multivariate analysis, age (P = 0.024), radiation dose (P = 0.001), and tumor size (P = 0.000) were the significant factors.CONCLUSION: 3D-CRT combined with TACE is an effective and feasible approach for HCC. Age, radiation dose and tumor size were found to be significant prognostic factors for survival of patients with HCC treated by 3D-CRT combined with TACE. Further study for HCC is needed to improve the treatment efficacy.
机译:目的:评估三维适形放疗(3D-CRT)联合经导管动脉化疗栓塞(TACE)对肝细胞癌(HCC)的疗效。方法:1998年至2001年间,94例HCC患者接受了3D- CRT与TACE结合使用。共有63例患者患有Okuda I期病变,31例患者处于II期。中位肿瘤大小为10.7厘米(范围3.0-18厘米),所有患者均存在肝硬化。 A类有43例,B类有51例。使用脂质体,5-氟尿嘧啶,顺铂,盐酸阿霉素和丝裂霉素,然后用明胶海绵块进行TACE。 59例患者仅接受TACE一次,而其他2〜3次。 TACE后3-4周启动了3D-CRT。所有患者均接受立体定向车架辐照,并在17-26 d(中位数22 d)期间在等中心接受4-8 Gy单次大剂量放射治疗8-12次。诊断后为37 mo(范围为10-48 mo)。回应率为90.5%。 1年,2年和3年的总生存率分别为93.6%,53.8%和26.0%,中位生存期为25 mo。单因素分析,年龄(P = 0.026),肝硬化的Child-Pugh分类(P = 0.010),奥田期(P = 0.026),肿瘤大小(P = 0.000),肿瘤类型(P = 0.029),白蛋白血症(P = 0.035),辐射剂量(P = 0.000)被证明是生存的重要因素。在多因素分析中,年龄(P = 0.024),放射剂量(P = 0.001)和肿瘤大小(P = 0.000)是重要因素。结论:3D-CRT联合TACE是治疗肝癌的一种有效可行的方法。发现年龄,放射剂量和肿瘤大小是3D-CRT联合TACE治疗HCC患者生存的重要预后因素。需要对HCC进行进一步研究以提高治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号